C-peptide long-acting - Cebix

Drug Profile

C-peptide long-acting - Cebix

Alternative Names: CBX 129801; Ersatta; PEGylated C-peptide

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Cebix
  • Class Pancreatic hormones
  • Mechanism of Action Adenosine triphosphatase stimulants; Nerve growth factor stimulants; Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Jan 2015 Cebix completes a phase II trial in Diabetic neuropathies in USA, Canada and Sweden (NCT01681290)
  • 11 Dec 2012 Phase-II clinical trials in Diabetic neuropathies in Sweden (SC) (EudraCT2012-001246-17)
  • 11 Dec 2012 Phase-II clinical trials in Diabetic neuropathies in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top